Newsbenzinga
Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.116B vs $28.950B Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…